Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Brandes

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Circulation|September 8, 2017
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart FailureMarie Bayer Elming, Jens C Nielsen, Jens Haarbo, et al.
The New England Journal of Medicine|September 1, 2020
Early Rhythm-Control Therapy in Patients with Atrial FibrillationPaulus Kirchhof, A John Camm, Andreas Goette, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 24, 2019
The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trialJohan S Bundgaard, Jens J Thune, Jens C Nielsen, et al.
Circulation|November 7, 2022
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International CollaborationAxel Brandes, Stavros Stavrakis, Ben Freedman, et al.
European Journal of Preventive Cardiology|September 9, 2025
Identifying rehabilitation needs as part of secondary prevention in individuals with Atrial Fibrillation - a Delphi consensus studyCaroline M Elnegaard, Signe S Risom, Britt Borregaard, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 13, 2026
Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6Andreas Goette, Marc D Lemoine, Alexander Fierenz, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 1, 2025
Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trialNina Becher, Gina Köllner, Emanuele Bertaglia, et al.
Journal of the American Heart Association|August 27, 2024
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 TrialHans Christoph Diener, Nina Becher, Susanne Sehner, et al.
The New England Journal of Medicine|August 25, 2023
Anticoagulation with Edoxaban in Patients with Atrial High-Rate EpisodesPaulus Kirchhof, Tobias Toennis, Andreas Goette, et al.
European Heart Journal|April 9, 2024
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trialGregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Circulation|September 8, 2017
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart FailureMarie Bayer Elming, Jens C Nielsen, Jens Haarbo, et al.
The New England Journal of Medicine|September 1, 2020
Early Rhythm-Control Therapy in Patients with Atrial FibrillationPaulus Kirchhof, A John Camm, Andreas Goette, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 24, 2019
The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trialJohan S Bundgaard, Jens J Thune, Jens C Nielsen, et al.
Circulation|November 7, 2022
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International CollaborationAxel Brandes, Stavros Stavrakis, Ben Freedman, et al.
European Journal of Preventive Cardiology|September 9, 2025
Identifying rehabilitation needs as part of secondary prevention in individuals with Atrial Fibrillation - a Delphi consensus studyCaroline M Elnegaard, Signe S Risom, Britt Borregaard, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 13, 2026
Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6Andreas Goette, Marc D Lemoine, Alexander Fierenz, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 1, 2025
Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trialNina Becher, Gina Köllner, Emanuele Bertaglia, et al.
Journal of the American Heart Association|August 27, 2024
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 TrialHans Christoph Diener, Nina Becher, Susanne Sehner, et al.
The New England Journal of Medicine|August 25, 2023
Anticoagulation with Edoxaban in Patients with Atrial High-Rate EpisodesPaulus Kirchhof, Tobias Toennis, Andreas Goette, et al.
European Heart Journal|April 9, 2024
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trialGregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, et al.
Pageof 15